Short Summary
The PTAB instituted an inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after Imperative Care showed a reasonable likelihood of success on multiple claims. The dispute centers on the definition of “filament” and reliance on prior art Schaffer, Hartley, and Eller.
Detailed Summary
In a Decision Granting Institution of Inter Partes Review, the Patent Trial and Appeal Board found that Imperative Care, Inc. demonstrated a reasonable likelihood of prevailing on at least one of the claims of Inari Medical’s ’921 patent covering hemostasis valves for minimally invasive vascular surgery. The petition challenged claims 1‑7, 9, 10, 15‑18, and 20‑24 under §§102 and 103, relying on prior art references Schaffer, Hartley, and Eller. A key issue was whether the term “filament” required flexibility; the Board preliminarily leaned toward the patent owner’s view that it does. Based on the record, the Board instituted review on all 19 challenged claims, setting the stage for a full trial on obviousness and anticipation arguments.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Imperative Care, Inc. vs Inari Medical, Inc. et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Apple Inc.vsSmith Interface Technologies, LLC
Apple Inc. successfully secured institution of its IPR challenge against Smith Interface Technologies, LLC regarding touch screen interface claims. The Board found that the petitioner demonstrated sufficient motivation to combine prior art references for obviousness challenges under 35 U.S.C. § 103. This paves the way for a full trial on key mobile computing patents.
HP Inc. et al.vsUniversal Connectivity Technologies Inc.
The PTAB denied institution for an IPR petition concerning serial data transmission and symbol encoding (Patent No. 7154905). The Board found that while the petitioner raised obviousness arguments, the merits of the case were not sufficiently strong to overcome procedural hurdles.
Inari Agriculture, Inc.vsPioneer Hi-Bred International, Inc.
The USPTO Director denied Inari Agriculture's request to review the PTAB's denial of institution for Pioneer Hi‑Bred's seed‑technology patent, leaving the denial in place.
Merck Sharp & Dohme LLC et al.vsThe Johns Hopkins University
Merck Sharp & Dohme LLC challenged The Johns Hopkins University's patent (11325975) in a Petition, arguing all claims are anticipated by the MSI-H Study Record and rendered obvious by combinations of prior art. The petitioner asserts that the study record inherently discloses every limitation of the claimed method for treating MSI-H patients with anti-PD-1 antibodies.
TCL Industries Holdings Co., Ltd.vsMaxell, Ltd.
The PTAB denied TCL Industries Holdings Co., Ltd.'s request to institute IPR against Maxell, Ltd.'s display apparatus patent. The denial was based on the advanced stage of parallel district court litigation and the petitioner's relative lateness in filing.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.